Double-blind, randomized, two-way cross-over study with two treatment periods. 28 subjects
with asthma will be randomized in 1:1 ratio to treatment A) Indacaterol/Mometasone 150/160 μg
once daily and treatment B) Indacaterol/Glycopyrronium/Mometasone 150/50/80 μg once daily for
period 1. For period 2, subjects will be crossed over to the other treatment arm. Subjects
will be screened during the first visit. After inclusion subjects will be seen for 3 visits
during the Run-in period, 3 visits during treatment period 1 and 3 visits during treatment
period 2. During these visits patients will be clinically characterized and exposed to
allergen challenge tests.